Calendario›AMGN›MP-376

MP-376

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Ensayo de AMGEN INC en Cystic Fibrosis (CF) (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

151

previstos

Centros

50

Fin del objetivo primario

jun 2009

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jun 2008.

Qué mide

Change in P. Aeruginosa Density (from baseline to end of treatment (28 days)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPatients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00677365), actualizada en dic 2024.